Active Biotech and Ipsen Report Tasquinimod (TASQ) Phase II Long Term Safety Data at the 27th European Association of Urology (EAU) Congress

LUND, Sweden & PARIS--(BUSINESS WIRE)--Regulatory News: Active Biotech’s (NASDAQ OMX NORDIC: ACTI) and Ipsen’s (Paris:IPN) (Euronext: IPN; ADR: IPSEY) castrate resistant prostate cancer project, TASQ, will be presented at the 27th Annual EAU Congress held in Paris on 24-28 February 2012. The presentation will detail the analysis of up to three years safety data from the TASQ Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC). The poster “Long term safety an

Feed Date: 
February 24, 2012